Clinical Trials Logo

Danon Disease clinical trials

View clinical trials related to Danon Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT06214507 Recruiting - Danon Disease Clinical Trials

Danon Disease Natural History Study

Start date: December 20, 2023
Phase:
Study type: Observational

The goal of this international observational study is to learn about the natural history of Danon disease in male patients >8 years of age. The key objectives include assessing change over time in cardiac structure (left ventricular mass and wall thickness), cardiac biomarkers, symptoms, and quality of life and the incidence of clinical events such as HF hospitalization, cardiac transplantation, and death.

NCT ID: NCT06092034 Recruiting - Danon Disease Clinical Trials

A Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Start date: September 5, 2023
Phase: Phase 2
Study type: Interventional

This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.

NCT ID: NCT05548855 Completed - Danon Disease Clinical Trials

Natural History of Danon Disease

Start date: September 26, 2022
Phase:
Study type: Observational

This is a multicenter, international, non-interventional, natural history study designed to collect longitudinal retrospective clinical information on patients with Danon disease (DD). This study is composed of 2 parts: - Feasibility study: to identify participating sites, assess site and team capabilities, confirm the site and investigator qualification for taking part in the study, - Retrospective chart review: Data will be collected retrospectively by means of a chart review of living and/or deceased DD patients with a confirmed lysosome associated membrane protein-2 gene (LAMP2) mutation, and, - For living patients (who have not undergone heart transplantation or placement of a cardiac assist device), availability of at least 6-month cardiology follow-up data, - For living patients who underwent heart transplantation or placement of a cardiac assist device, and for deceased patients, at least 1 MRI or echo assessment prior to heart transplantation/cardiac assist device placement or death.

NCT ID: NCT03882437 Active, not recruiting - Danon Disease Clinical Trials

Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

This is a non-randomized open-label Phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon Disease (DD).

NCT ID: NCT03766386 Recruiting - Danon Disease Clinical Trials

The Natural History of Danon Disease

Start date: November 30, 2018
Phase:
Study type: Observational [Patient Registry]

Danon disease (DD) is a rare, X-linked disorder associated with severe cardiomyopathy, and in many cases, skeletal myopathy, and cognitive impairment caused by mutations in the LAMP2 gene. There is still uncertainty regarding the natural history of DD because of its rarity. This study aims to determine the natural history of DD through the collection and analysis of retrospective and prospective data. To achieve this, the investigators will perform surveys and obtain medical records from DD patients. The same cohort of patients will also be assessed by a multidisciplinary team with expertise in DD (cardiologist, neurologist, ophthalmologist, psychologist, geneticist) at the University of California, San Diego. All patients with DD are eligible, including those who underwent a heart transplant. Additionally, data and records from deceased patients will provide valuable retrospective data for this study.